Main content

    Multiple Myeloma Clinical Trials

    Adult Clinical Trials Main Page

    CPMC Cancer Services

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Principal Investigator/Contact InformationProtocol TitlePatient Population Recruitment Period
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775
    Email engb@cpmcri.org    		 Myeloma Specimen Repository Protocol, Ancillary. SWOG S0309.Subjects with multiple Myeloma Open
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775
    Email engb@cpmcri.org    		 A Phase II Trial Evaluating Modified High Dose Melphalan (100mg/M2) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study) Stage II-III MM Diagnosed Within 1yr Of Registration, Protein Criteria Present And/Or Histologically Confirmed Primary Systemic Amyloidosis. SWOG S0115 High risk subjects with multiple Myeloma and/ or light chain Amyloidosis stage II-III diagnosed within 1 yr or registration, protein criteria present and/or histologically confirmed primary Systematic AmyloidosisOpen
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775
    Email engb@cpmcri.org    		 A Randomized Phase III Trial of CC_5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) versus Bortezomib, Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously untreated Multiple Myeloma without an Intent for Imeediate Autologous Stem Cell Transplant. SWOG S0777Subjects with previously untreated Multiple Myeloma without an Intent for Imeediate Autologous Stem Cell TransplantClosed to Enrollment



    updated: 9/2010

    Back to top